Trials / Completed
CompletedNCT03977935
The Second-Generation MCCG for Upper Gastrointestinal Tract.
Second-generation Versus First-generation Magnetically Controlled Capsule Gastroscopy for Upper Gastrointestinal Tract: a Randomized Controlled Clinical Trial.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to evaluate the clinical application of the second-generation MCCG with higher image resolution and frame rate for upper gastrointestinal tract compared with the first-generation.
Detailed description
Magnetically controlled capsule gastroscopy (MCCG) has been widely used in clinical practice for gastric examination. However, there still exist blind spots under MCCG, particularly in the esophagus and duodenum. Although the anatomy of the esophagus and duodenum can be the main cause, MCCG still needs technical improvement. In addition, the gastric examination time under MCCG can be further optimized. Therefore, a new-generation MCCG is developed with a higher frame rate improved from 0.5-2 to 0.5-8 frames per second, image resolution improved from 480 x 480 to 720 x 720, view angle improved from 140° to 150°, wireless anti-jamming technology is applied as a more effective and stable information transmission method. This is a prospective, single-centered, blinded randomized controlled pilot study. Subjects receiving MCCG at Changhai Hospital will be randomly allocated into two groups with a ratio of 1:1 before the procedure, the first-generation or the second-generation MCCG. After passage through the esophagus, the gastric examination and transpyloric passage of the capsule is conducted under magnetic steering, and then examination is continued in the small bowel under intestinal peristalsis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | the second-generation MCCG | Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2). |
Timeline
- Start date
- 2019-05-10
- Primary completion
- 2019-07-18
- Completion
- 2019-07-25
- First posted
- 2019-06-06
- Last updated
- 2020-10-27
- Results posted
- 2020-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03977935. Inclusion in this directory is not an endorsement.